Intellectual Property Portfolio

Core aspects and embodiments of the Lectenz® development platform are the subject of an issued patent (Glycan-Specific Analytical Tools) assigned jointly to the University of Georgia Research Foundation (UGARF) and the company.  The company is actively building an intellectual property portfolio to maximize freedom to operate. Patents associated with the company’s technologies include:

  • Glycan-Specific Analytical Tools. U.S. Patent No. 9,926,612 B2, Japanese Patent No. 6360462, Israeli Patent Application No. 212806, European Patent No. 2367562 B1.
  • Carbohydrate-Binding Polypeptide. U.S. Patent No. 10,358,637.
  • Glycomimetics to Inhibit Pathogen-Host Interactions. U.S. Patent No. 9,605,014.
  • Sialic Acid Binding Polypeptide. PCT Application PCT/US2018/029079.
  • Glycoprofiling with Multiplexed Suspension Arrays. PCT Application PCT/US2012/027211

Additional Lectenz®-specific patent applications are expected to be filed as novel Lectenz® reagents, are engineered and characterized. These Lectenz® reagents will be included in the GlycoSenseTM kits. A federally registered trademark for Lectenz® was issued in 2009. Trade secrets protect certain elements of the process for producing GlycoSenseTM kits and Lectenz® reagents, including knowledge gained through in silico and in vitro experimentation.